158 related articles for article (PubMed ID: 28266149)
1. IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer.
Mounika Inavolu S; Renbarger J; Radovich M; Vasudevaraja V; Kinnebrew GH; Zhang S; Cheng L
CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):168-176. PubMed ID: 28266149
[TBL] [Abstract][Full Text] [Related]
2. GSNFS: Gene subnetwork biomarker identification of lung cancer expression data.
Doungpan N; Engchuan W; Chan JH; Meechai A
BMC Med Genomics; 2016 Dec; 9(Suppl 3):70. PubMed ID: 28117655
[TBL] [Abstract][Full Text] [Related]
3. Identification of hub subnetwork based on topological features of genes in breast cancer.
Zhuang DY; Jiang L; He QQ; Zhou P; Yue T
Int J Mol Med; 2015 Mar; 35(3):664-74. PubMed ID: 25573623
[TBL] [Abstract][Full Text] [Related]
4. BMRF-MI: integrative identification of protein interaction network by modeling the gene dependency.
Shi X; Wang X; Shajahan A; Hilakivi-Clarke L; Clarke R; Xuan J
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S10. PubMed ID: 26099273
[TBL] [Abstract][Full Text] [Related]
5. Identification of significantly mutated subnetworks in the breast cancer genome.
Ajwad R; Domaratzki M; Liu Q; Feizi N; Hu P
Sci Rep; 2021 Jan; 11(1):642. PubMed ID: 33436820
[TBL] [Abstract][Full Text] [Related]
6. GTA: a game theoretic approach to identifying cancer subnetwork markers.
Farahmand S; Goliaei S; Ansari-Pour N; Razaghi-Moghadam Z
Mol Biosyst; 2016 Mar; 12(3):818-25. PubMed ID: 26750920
[TBL] [Abstract][Full Text] [Related]
7. Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer.
Liu P; Jiang W; Zhou S; Gao J; Zhang H
Pathol Oncol Res; 2017 Apr; 23(2):361-368. PubMed ID: 27654269
[TBL] [Abstract][Full Text] [Related]
8. Smell Detection Agent Optimisation Framework and Systems Biology Approach to Detect Dys-Regulated Subnetwork in Cancer Data.
Sivan SL; Sukumara Pillai VCS
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053185
[TBL] [Abstract][Full Text] [Related]
9. Toward precision medicine of breast cancer.
Carels N; Spinassé LB; Tilli TM; Tuszynski JA
Theor Biol Med Model; 2016 Feb; 13():7. PubMed ID: 26925829
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer.
Peng C; Ma W; Xia W; Zheng W
Mol Med Rep; 2017 Mar; 15(3):1087-1094. PubMed ID: 28075450
[TBL] [Abstract][Full Text] [Related]
11. Identifying protein interaction subnetworks by a bagging Markov random field-based method.
Chen L; Xuan J; Riggins RB; Wang Y; Clarke R
Nucleic Acids Res; 2013 Jan; 41(2):e42. PubMed ID: 23161673
[TBL] [Abstract][Full Text] [Related]
12. Identification of breast cancer candidate genes using gene co-expression and protein-protein interaction information.
Yue Z; Li HT; Yang Y; Hussain S; Zheng CH; Xia J; Chen Y
Oncotarget; 2016 Jun; 7(24):36092-36100. PubMed ID: 27150055
[TBL] [Abstract][Full Text] [Related]
13. Identification of sample-specific regulations using integrative network level analysis.
Liu C; Louhimo R; Laakso M; Lehtonen R; Hautaniemi S
BMC Cancer; 2015 Apr; 15():319. PubMed ID: 25928379
[TBL] [Abstract][Full Text] [Related]
14. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
15. Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms.
Grimm LJ; Zhang J; Mazurowski MA
J Magn Reson Imaging; 2015 Oct; 42(4):902-7. PubMed ID: 25777181
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis.
Wu D; Han B; Guo L; Fan Z
J Obstet Gynaecol; 2016 Jul; 36(5):615-21. PubMed ID: 26804550
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide screen identifies a novel prognostic signature for breast cancer survival.
Mao XY; Lee MJ; Zhu J; Zhu C; Law SM; Snijders AM
Oncotarget; 2017 Feb; 8(8):14003-14016. PubMed ID: 28122328
[TBL] [Abstract][Full Text] [Related]
18. Is precision medicine ready for use in breast cancer?
Pusztai L
Clin Adv Hematol Oncol; 2016 Dec; 14(12):964-966. PubMed ID: 28212357
[No Abstract] [Full Text] [Related]
19. Identification of differentially expressed subnetworks based on multivariate ANOVA.
Hwang T; Park T
BMC Bioinformatics; 2009 Apr; 10():128. PubMed ID: 19405941
[TBL] [Abstract][Full Text] [Related]
20. Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients.
Xu Y; Lin S; Zhao H; Wang J; Zhang C; Dong Q; Hu C; Desi S; Wang L; Xu Y
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31466383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
